Loading
CDKN2B (Cyclin-dependent kinase 4 inhibitor B) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma, Breast cancer and 5 more.
Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest.
CIViC holds 8 clinical evidence items and 0 assertions across 5 variants, naming Palbociclib, Trametinib, Bevacizumab and Vemurafenib and others. Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes genetic literature 0.30, affected pathway 0.76, literature 0.98, genetic association 0.70, somatic mutation 0.62).
In plain words · CDKN2B (Cyclin-dependent kinase 4 inhibitor B) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma, Breast cancer and 5 more.
CDKN2B (Cyclin-dependent kinase 4 inhibitor B) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma, Breast cancer and 5 more.
Interacts strongly with CDK4 and CDK6. Potent inhibitor.
No product in this corpus aims at CDKN2B yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA CDKN2B: RNA tissue enhanced (esophagus 37 nTPM, intestine 29 nTPM); blood lineage lineage enriched (monocytes 9 nTPM); no normal tissue stained high; highest cancer staining liver cancer (3 of 11 high). Distribution: 7 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Biliary tract cancer (all types), Pancreatic ductal adenocarcinoma, Renal cell carcinoma, Breast cancer (all types), Skin cancer (all types), Sarcomas (soft tissue, bone, GIST), Leukaemia); Open Targets associates it with 4 specific cancer types at or above 0.5 (breast cancer, glioma, basal cell carcinoma, central nervous system cancer). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas CDKN2B tissue; Open Targets ENSG00000147883 associations
First described 1994. Earliest sequence paper UniProt cites for the protein: Guan K.-L. et al, Genes Dev, 1994, "Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function". Source.
Sources: HGNC HGNC:1788 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P42772 (protein name, function text, keywords and locations (REST API)); CIViC gene CDKN2B (8 evidence items, 0 assertions, 5 variants; diseases: Pancreatic Cancer, Cholangiocarcinoma, Ewing Sarcoma, Renal Cell Carcinoma, Acute Promyelocytic Leukaemia and 2 more (GraphQL API, CC0)); Open Targets ENSG00000147883 (association with cancer (MONDO_0004992) 0.67; per-cancer scores at or above 0.5: skin cancer 0.51, basal cell carcinoma 0.50, breast cancer 0.60 (GraphQL API, CC0))
Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest. Location: Cytoplasm (UniProt). Locus 9p21.3 (HGNC).
RNA: tissue enhanced (esophagus 37 nTPM, intestine 29 nTPM), detected in many normal tissues. Blood: lineage enriched (monocytes 9 nTPM).
No normal tissue stained high.
RNA cancer enhanced: Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma 47 pTPM.
Medium only: cervical cancer, head and neck cancer, lung cancer, ovarian cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Gallbladder cancer | 14% | Deep deletion (with CDKN2A) | Deep deletion in 34 of 244 samples, 13.9%, in cBioPortal gbc_mskcc_2022 and 12 of 103, 11.7%, in gbc_msk_2018; co-deleted with CDKN2A on 9p21. | cBioPortal (TCGA) |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Query for this target: (TITLE:"CDKN2B" OR ABSTRACT:"CDKN2B" OR TITLE:"cyclin dependent kinase inhibitor 2B" OR ABSTRACT:"cyclin dependent kinase inhibitor 2B" OR TITLE:"Cyclin-dependent kinase 4 inhibitor B" OR ABSTRACT:"Cyclin-dependent kinase 4 inhibitor B" OR TITLE:"P15" OR ABSTRACT:"P15" OR TITLE:"MTS2" OR ABSTRACT:"MTS2" OR TITLE:"INK4B" OR ABSTRACT:"INK4B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CDKN2B, not a curated reading list.
Shares Ewing sarcoma, CIViC, Breast cancer (all types), Pancreatic ductal adenocarcinoma.
Shares Acute promyelocytic leukaemia, Skin cancer (all types), CIViC, Open Targets Platform.
Shares Acute promyelocytic leukaemia, Open Targets Platform.
Shares Acute promyelocytic leukaemia, Open Targets Platform.
Shares Ewing sarcoma, CIViC.
Shares Small cell lung cancer (KEGG map), CIViC.